Entrada Therapeutics
TRDATRDA · Stock Price
Historical price data
Overview
Entrada Therapeutics is a clinical-stage biotechnology company with a mission to overcome the fundamental challenge of intracellular drug delivery. Its core innovation is the Endosomal Escape Vehicle (EEV) platform, a versatile technology enabling the efficient delivery of therapeutic molecules into the cell cytoplasm. The company is advancing a pipeline of oligonucleotide-based candidates for serious genetic neuromuscular disorders, with its lead program, ENTR-601-44 for DMD exon 44 skipping, in Phase 1/2b trials. Entrada's strategy leverages its platform to target high-unmet-need diseases with validated biology but historically inaccessible targets.
Technology Platform
Proprietary Endosomal Escape Vehicle (EEV) platform based on cyclic cell-penetrating peptides, engineered to deliver diverse therapeutic cargo (oligonucleotides, peptides, proteins) into the cell cytoplasm by facilitating escape from the endosomal compartment.
Pipeline
2| Drug | Indication | Stage | Watch |
|---|---|---|---|
| ENTR-601-44 + ENTR-601-44 - matching placebo | Duchenne Muscular Dystrophy (DMD) | Phase 1/2 | |
| ENTR-601-45 + ENTR-601-45 - matching placebo | Duchenne Muscular Dystrophy (DMD) | Phase 1/2 |
Opportunities
Risk Factors
Competitive Landscape
Faces competition in DMD from Sarepta's PMO-based exon-skippers and in DM1 from Avidity and Dyne's conjugate platforms. Entrada's key differentiator is its cyclic peptide-based EEV technology, aiming for superior cellular uptake and endosomal escape compared to existing modalities.
